Proton Beam Therapy for Sinonasal Neuroendocrine Carcinoma: A Six-Case Series with Dosimetric Comparison and Literature Review
Journal of Clinical Medicine · 07.01.2026 · 15 (2) · 477
DOI: 10.3390/jcm15020477 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.01.2026. Verfasst von Hazuki Nitta und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Tsukuba, Tsukuba 305-8577, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sinonasal neuroendocrine carcinoma (SNEC) is an extremely rare malignancy, and, to date, no clinical reports have detailed the use of proton beam therapy (PBT) for this disease. The present study describes the clinical courses of patients with SNEC treated with PBT and highlights the advantages of PBT.
Methods
In this retrospective study, we included patients with pathologically confirmed SNEC without distant metastasis who underwent PBT at our institution between 2006 and 2021. To evaluate the dosimetric advantages of PBT, comparative treatment plans using VMAT were created.
Result
Six patients with pathologically diagnosed SNEC without distant metastasis were treated with PBT. Multimodal treatment was applied in five patients, including chemotherapy in four cases and surgery in two cases. The median follow-up period was 37.4 months (range: 6.9 to 108.9 months). At the end of the follow-up, three patients were alive without recurrence, while three had died due to the disease. Recurrence occurred in three cases: one local recurrence, one in cervical lymph nodes, and two distant metastases. A late adverse event of Grade 4 vision decrease was observed in one patient on the ipsilateral side. Compared with VMAT, PBT lowered the average brain dose (median 3.3 Gy (RBE) vs. 12.6 Gy), brainstem D2 cc (10.7 Gy (RBE) vs. 34.9 Gy) and contralateral optic nerve D0.1 cc (47.6 Gy (RBE) vs. 63.3 Gy), while doses to the ipsilateral optic pathway were comparable.
Conclusions
PBT in multimodal treatment achieved feasible local control for SNEC. The dose-sparing effect of PBT was more evident in organs distant from the target, although careful consideration is required for adjacent structures.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Tsukuba, Tsukuba 305-8577, Japan.
- Department of Diagnostic Pathology, University of Tsukuba, Tsukuba 305-8577, Japan.
- Department of Otolaryngology, Head and Neck Surgery, University of Tsukuba, Tsukuba 305-8577, Japan.
ORCID-Profile: Takashi Saito, Ryota Matsuoka, Shin Matsumoto, Shuho Tanaka, Masahiro Nakayama, Motohiro Murakami, Masatoshi Nakamura, Masashi Mizumoto
Zitieren
APA
Nitta, H., Saito, T., Matsuoka, R., Matsumoto, S., Tanaka, S., Nakayama, M., Osawa, K., Murakami, M., Baba, K., Nakamura, M., Fujii, K., Oshiro, Y., Mizumoto, M., Tabuchi, K., Matsubara, D., & Sakurai, H. (2026). Proton Beam Therapy for Sinonasal Neuroendocrine Carcinoma: A Six-Case Series with Dosimetric Comparison and Literature Review. Journal of Clinical Medicine, 15(2), 477. https://doi.org/10.3390/jcm15020477
Vancouver
Nitta H, Saito T, Matsuoka R, Matsumoto S, Tanaka S, Nakayama M, et al. Proton Beam Therapy for Sinonasal Neuroendocrine Carcinoma: A Six-Case Series with Dosimetric Comparison and Literature Review. Journal of Clinical Medicine. 2026;15(2):477. doi:10.3390/jcm15020477
BibTeX
@article{Nitta2026,
author = {Nitta, Hazuki and Saito, Takashi and Matsuoka, Ryota and Matsumoto, Shin and Tanaka, Shuho and Nakayama, Masahiro and Osawa, Kotaro and Murakami, Motohiro and Baba, Keiichiro and Nakamura, Masatoshi and Fujii, Keitaro and Oshiro, Yoshiko and Mizumoto, Masashi and Tabuchi, Keiji and Matsubara, Daisuke and Sakurai, Hideyuki},
title = {Proton Beam Therapy for Sinonasal Neuroendocrine Carcinoma: A Six-Case Series with Dosimetric Comparison and Literature Review},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {2},
pages = {477},
doi = {10.3390/jcm15020477}
}
EUVIMED